enVVeno Medical Corporation

DB:5HJ Stock Report

Market Cap: €56.9m

enVVeno Medical Management

Management criteria checks 2/4

enVVeno Medical's CEO is Robert Berman, appointed in Apr 2018, has a tenure of 6.58 years. total yearly compensation is $1.87M, comprised of 26.7% salary and 73.3% bonuses, including company stock and options. directly owns 0.058% of the company’s shares, worth €33.22K. The average tenure of the management team and the board of directors is 5.5 years and 6.1 years respectively.

Key information

Robert Berman

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage26.7%
CEO tenure6.6yrs
CEO ownership0.06%
Management average tenure5.5yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Robert Berman's remuneration changed compared to enVVeno Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$21m

Mar 31 2024n/an/a

-US$22m

Dec 31 2023US$2mUS$500k

-US$24m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$25m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$466kUS$450k

-US$25m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$24m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$10mUS$400k

-US$17m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$1mUS$400k

-US$10m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$415kUS$400k

-US$8m

Sep 30 2019n/an/a

-US$7m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$13m

Dec 31 2018US$906kUS$293k

-US$16m

Compensation vs Market: Robert's total compensation ($USD1.87M) is above average for companies of similar size in the German market ($USD472.15K).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.


CEO

Robert Berman (61 yo)

6.6yrs

Tenure

US$1,870,884

Compensation

Mr. Robert A. Berman serves as Chief Executive Officer and Director of enVVeno Medical Corporation (formerly known as Hancock Jaffe Laboratories, Inc.) since April 2018. From September 2017 to March 2018,...


Leadership Team

NamePositionTenureCompensationOwnership
Robert Berman
CEO & Director6.6yrsUS$1.87m0.058%
€ 33.2k
Craig Glynn
CFO, Treasurer & Secretary4.6yrsUS$527.29k0%
€ 0
Hamed Alavi
Senior VP & Chief Technology Officer1.8yrsUS$669.19kno data
Marc Glickman
Senior VP & Chief Medical Officer8.5yrsUS$776.38k0.0091%
€ 5.2k
Warren Hancock
Co-founder37.8yrsno datano data
Sandy Prietto
Vice President of Marketingless than a yearno datano data
Benedict Broennimann
Chief Medical Officer of Outside of United States6.5yrsUS$240.00kno data
Andrew Cormack
Chief Commercial Officerless than a yearno datano data

5.5yrs

Average Tenure

63yo

Average Age

Experienced Management: 5HJ's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Berman
CEO & Director6.6yrsUS$1.87m0.058%
€ 33.2k
Robert Gray
Independent Director5.2yrsUS$77.50k0.044%
€ 24.8k
Matthew Jenusaitis
Independent Director5.2yrsUS$75.00k0.039%
€ 22.5k
Francis Duhay
Independent Director6.1yrsUS$70.00k0.12%
€ 67.9k
Sanjay Shrivastava
Independent Director6.1yrsUS$75.00k0.022%
€ 12.6k

6.1yrs

Average Tenure

62yo

Average Age

Experienced Board: 5HJ's board of directors are considered experienced (6.1 years average tenure).